Cargando…

Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial

Detalles Bibliográficos
Autores principales:	Keohane, Denis, Schwartz, Jeffrey, Gundapaneni, Balarama, Stewart, Michelle, Amass, Leslie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642035/ http://dx.doi.org/10.1186/1750-1172-10-S1-P11

Ejemplares similares

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
por: Amass, Leslie, et al.
Publicado: (2018)

Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
por: Waddington-Cruz, Marcia, et al.
Publicado: (2015)

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
por: Waddington Cruz, Márcia, et al.
Publicado: (2016)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015)

Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy
por: Gundapaneni, B. K., et al.
Publicado: (2017)

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
por: Sultan, Marla B, et al.
Publicado: (2017)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
por: Suhr, Ole B., et al.
Publicado: (2014)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H.‐J., et al.
Publicado: (2016)

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Mundayat, Rajiv, et al.
Publicado: (2018)

Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial
por: Shah, Sanjiv J., et al.
Publicado: (2023)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
por: Damy, Thibaud, et al.
Publicado: (2020)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H., et al.
Publicado: (2018)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
por: González‐Duarte, Alejandra, et al.
Publicado: (2020)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT
por: Nativi‐Nicolau, Jose, et al.
Publicado: (2021)

Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis
por: Zhao, Yinan, et al.
Publicado: (2019)

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy
por: Conceição, Isabel, et al.
Publicado: (2016)

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
por: Waddington-Cruz, Márcia, et al.
Publicado: (2019)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
por: Rozenbaum, Mark H, et al.
Publicado: (2021)

Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington‐Cruz, Márcia, et al.
Publicado: (2021)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Tafamidis and tafamidis meglumine for amyloid cardiomyopathy
Publicado: (2021)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
por: Merlini, Giampaolo, et al.
Publicado: (2020)

Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
por: Rozenbaum, Mark H., et al.
Publicado: (2022)

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
por: Wang, Jie, et al.
Publicado: (2023)

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy
por: Takashio, Seiji, et al.
Publicado: (2023)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy
por: Morier, Agnès, et al.
Publicado: (2015)

Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy
por: Shintani, Yasuhiro, et al.
Publicado: (2018)

Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
por: Vong, Camille, et al.
Publicado: (2021)

Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias
por: Isotani, Yoshitaka, et al.
Publicado: (2022)

A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis
por: Waddington Cruz, Márcia, et al.
Publicado: (2015)

Familial Amyloid Polyneuropathy treatment with Tafamidis – evaluation of one- and two-year treatment in Porto, Portugal
por: Coelho, Teresa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3mhr287v6rvieoufj7r15cfmc7